Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Azacitidine in Treatment-Naïve AML Ineligible for Standard Induction
NCT02993523Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Feb 2017
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of venetoclax in acute myeloid leukemia (AML), sponsored by AbbVie Inc.. Started Feb 2017; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02993523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993523.